Clinical trial · Interventional
A Study of AK112 for Advanced Solid Tumors
A Phase I/II Trial of AK112 in Advanced Solid Tumor
NCT04597541CI-TRIAL-00086982completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary end points are objective response rate,progression-free survival and overall survival per RECIST1.1.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AK112 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- AK112
- interventionNames
- Drug: AK112
Primary outcomes (2)
- measure
- Number of participants with adverse events (AEs)
- timeFrame
- From time ICF is signed until 90 days after last dose of AK112
- description
- An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. temporally associated with the use of study treatment, whether or not considered related to the study treatment
- measure
- Number of participants with DLTs
- timeFrame
- During the first four weeks of treatment
- description
- DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 to 75 years old (at the time consent is obtained); * Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures); * Have histologically- or cytologically-confirmed diagnosis of advanced solid tumor; * Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy; * Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or * Subject must have at least one measurable lesion according to RECIST Version1.1; * Adequate organ function; * Females of childbearing potential and non-sterilized males who are sexually active must use an effective method; * Adequate life expectancy. Exclusion Criteria: * History of severe hypersensitivity reactions to other mAbs; * Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria; * Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery; * Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK112 except for treatment with small-molecule tyrosine kinase-targeted agents within 2 weeks prior to the first dose of AK112; * History of primary immunodeficiency; * Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis); * History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives; * Known allergy or reaction to any component of the AK112 formulation; * History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies; * Known history of tuberculosis; * Known history of HIV; * Receipt of live attenuated vaccination within 30 days prior to the first dose of AK112; * Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
References
Publications (1)
- DERIVEDWang F, Wei X, Zheng Y, Wang J, Ying J, Chen X, Luo S, Luo H, Yu X, Chen B, Ma L, Xu R. Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors. Cancer Med. 2025 Mar;14(6):e70653. doi: 10.1002/cam4.70653. PMID 40114411